OncoMatch/Clinical Trials/NCT06314906
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
Is NCT06314906 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Electroacupuncture and Antiemetic Therapy for electroacupuncture.
Treatment: Electroacupuncture · Antiemetic Therapy · Sham electroacupuncture · Antiemetic Therapy — This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage EARLY-STAGE
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: acupuncture
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06314906 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior acupuncture disqualifies patients from enrollment.
What disease stage is eligible?
Stage EARLY-STAGE is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify